A Case of Immune Checkpoint Inhibitor Myocarditis Detected on Routine Troponin Monitoring

Han Zhu, MD1,2,3, Sarah Walinary, MD/MS1, Joel W. Neal, MD1,2, Heather A. Wakelee, MD1,2,4, Sean M. Wu, MD/PhD1,2,3,4, Ronald M. Witteles, MD1,2

1 Stanford Cardiovascular Institute; 2 Department of Medicine; 3 Department of Cardiovascular Medicine; 4 Department of Oncology, Stanford, CA, USA; Correspondence: witteles@stanford.edu.

Introduction

Immune checkpoint inhibitors (ICIs) are novel drugs that activate T cell-mediated anti-tumor response leading to improved cancer patient survival. Despite these benefits and their increased usage over the past decade (Figure 1), myocarditis can be a serious side effect of immunotherapy, ranging in clinical presentation from subclinical to fulminant. Although retrospective data suggests that elevated troponin is found in up to 94% of patients and is associated with worse CV outcomes, routine screening with troponin levels is not standard practice. Here, we present a case of ICI myocarditis detected on routine troponin monitoring.

History and Presentation

A 76-year-old male with stage III lung adenocarcinoma and no cardiac history received standard radiation/chemotherapy followed by initiation of the immune checkpoint inhibitor durvalumab (a PD-L1 inhibitor) 10 mg/kg biweekly (per standard of care – PACIFIC trial). Routine 10-week labs at fifth cycle of durvalumab showed a troponin of 1.232 ng/mL (ref <0.055 ng/mL), with no baseline for comparison. Patient had no signs of other autoimmunity. A repeat troponin one week later was 0.45 ng/mL. EKG showed no ischemic changes. The patient declined admission as he was asymptomatic and felt well. A repeat troponin one week later was 0.145 ng/mL. EKG showed no ischemic changes. He was admitted for coronary evaluation, although he remained asymptomatic. His EKG showed normal sinus rhythm at a heart rate of 78 bpm and no wall motion abnormalities. His troponin peaked at 10.666 ng/mL and down-trended to 5.842 ng/mL over 24 hours on prednisone 60 mg daily. The patient was initiated on high dose corticosteroids.

Laboratory & Imaging Results

One week later, his troponin prior to the sixth cycle of durvalumab was 10.394 ng/mL. He was admitted for coronary evaluation, although he remained asymptomatic. His EKG showed normal sinus rhythm at a heart rate of 78 bpm and no ischemic ST or T wave changes. A CT coronary angiogram showed no significant coronary artery disease (with calcium score of 0). A repeat TTE demonstrated normal left ventricular ejection fraction of 59% and no wall motion abnormalities. A cardiac MRI detected abnormal delayed myocardial enhancement (DGE) in the basal anterolateral wall associated with subtle T2 hyperintensity, suggestive of myocardial edema. A repeat cardiac MRI one month later showed persistent LGE in the anterolateral wall. Follow-up cardiac MRI one month one month later showed persistent LGE in the anterolateral wall and resolution of myocardial edema and pericardial effusion.

Discussion

Significant cardiac biomarker elevations may be seen in patients receiving immunotherapy without overt clinical signs and symptoms. A high level of attention is required, given that the delayed initiation of steroids may lead to higher rates of MACE. Routine biomarker monitoring may detect cases of subclinical myocarditis with early imaging signs of myocardial dysfunction and improve cardiac safety for patients on immunotherapy.

Acknowledgements

I would like to thank my mentors, colleagues, and trainees in the Stanford Cardiovascular Institute, Department of Cardiovascular Medicine, and Department of Oncology for their continued help and support on this project. I would also like to thank all the Stanford house staff for their assistance and vigilance in identifying patients with ICI cardiotoxicity admitted to Stanford Hospital. My funding sources include the Stanford Cancer Institute Innovation Grant and the NIH F32 Ruth L. Kirschstein National Research Service Award (NRSA).

Disclosures

The first author (Han Zhu) and leading author (Ronald M. Witteles) of this poster have no financial disclosures.